Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial.
Publication/Presentation Date
9-1-2025
Abstract
Background US contrast agents are gas-filled microbubbles that can be disrupted locally, such as via ultrasound-triggered microbubble destruction (UTMD), which can cause bioeffects that sensitize tumors to radiation. However, the efficacy and safety of UTMD combined with radiation therapy in participants with hepatocellular carcinoma (HCC) are unknown. Purpose To determine the treatment efficacy and safety of UTMD in participants with HCC receiving yttrium 90 (
Volume
316
Issue
3
First Page
250083
Last Page
250083
ISSN
1527-1315
Published In/Presented At
Wessner, C. E., Forsberg, F., Lyshchik, A., O'Kane, P., Bradigan, K., Liu, J. B., Delaney, L. J., Anton, K., Topper, S. R., Civan, J., Maley, W., Keith, S. W., Shaw, C. M., & Eisenbrey, J. R. (2025). Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial. Radiology, 316(3), e250083. https://doi.org/10.1148/radiol.250083
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
41025990
Department(s)
Administration and Leadership
Document Type
Article